These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 21143168)

  • 1. Pleiotropic effects of ARB in metabolic syndrome.
    Yamada S
    Curr Vasc Pharmacol; 2011 Mar; 9(2):158-61. PubMed ID: 21143168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of renin-angiotensin system inhibition in the treatment of hypertension in metabolic syndrome: are all the angiotensin receptor blockers equal?
    Karagiannis A; Mikhailidis DP; Athyros VG; Kakafika AI; Tziomalos K; Liberopoulos EN; Florentin M; Elisaf M
    Expert Opin Ther Targets; 2007 Feb; 11(2):191-205. PubMed ID: 17227234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiotensin receptor and tumor necrosis factor-α activation contributes to glucose intolerance independent of systolic blood pressure in obese rats.
    Rodriguez R; Lee A; Mathis KW; Broome HJ; Thorwald M; Martinez B; Nakano D; Nishiyama A; Ryan MJ; Ortiz RM
    Am J Physiol Renal Physiol; 2018 Oct; 315(4):F1081-F1090. PubMed ID: 29993275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property.
    Yamagishi S; Takeuchi M
    Med Hypotheses; 2005; 64(3):476-8. PubMed ID: 15617852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic review of the effect of telmisartan on insulin sensitivity in hypertensive patients with insulin resistance or diabetes.
    Suksomboon N; Poolsup N; Prasit T
    J Clin Pharm Ther; 2012 Jun; 37(3):319-27. PubMed ID: 21848583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin.
    Clasen R; Schupp M; Foryst-Ludwig A; Sprang C; Clemenz M; Krikov M; Thöne-Reineke C; Unger T; Kintscher U
    Hypertension; 2005 Jul; 46(1):137-43. PubMed ID: 15939809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system.
    Kurtz TW; Pravenec M
    J Hypertens; 2004 Dec; 22(12):2253-61. PubMed ID: 15614015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Involvement of the pancreatic renin-angiotensin system in insulin resistance and the metabolic syndrome.
    Leung PS; de Gasparo M
    J Cardiometab Syndr; 2006; 1(3):197-203. PubMed ID: 17679833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New treatment strategies for patients with hypertension and insulin resistance.
    Kurtz TW
    Am J Med; 2006 May; 119(5 Suppl 1):S24-30. PubMed ID: 16563944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The renin-angiotensin system: a target of and contributor to dyslipidemias, altered glucose homeostasis, and hypertension of the metabolic syndrome.
    Putnam K; Shoemaker R; Yiannikouris F; Cassis LA
    Am J Physiol Heart Circ Physiol; 2012 Mar; 302(6):H1219-30. PubMed ID: 22227126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Obesity and gastrointestinal hormones-dual effect of angiotensin II receptor blockade and a partial agonist of PPAR-γ.
    Nakagami H; Morishita R
    Curr Vasc Pharmacol; 2011 Mar; 9(2):162-6. PubMed ID: 21143167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treating the metabolic syndrome using angiotensin receptor antagonists that selectively modulate peroxisome proliferator-activated receptor-gamma.
    Pershadsingh HA
    Int J Biochem Cell Biol; 2006; 38(5-6):766-81. PubMed ID: 16298156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential utility of telmisartan, an angiotensin II type 1 receptor blocker with peroxisome proliferator-activated receptor-gamma (PPAR-gamma)-modulating activity for the treatment of cardiometabolic disorders.
    Yamagishi S; Nakamura K; Matsui T
    Curr Mol Med; 2007 Aug; 7(5):463-9. PubMed ID: 17691961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroprotective effects of angiotensin receptor blockers.
    Villapol S; Saavedra JM
    Am J Hypertens; 2015 Mar; 28(3):289-99. PubMed ID: 25362113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin-receptor blocking agents and the peroxisome proliferator-activated receptor-gamma system.
    Tuck ML
    Curr Hypertens Rep; 2005 Aug; 7(4):240-3. PubMed ID: 16061040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blockade of the RAS increases plasma adiponectin in subjects with metabolic syndrome and enhances differentiation and adiponectin expression of human preadipocytes.
    Tian F; Luo R; Zhao Z; Wu Y; Ban Dj
    Exp Clin Endocrinol Diabetes; 2010 Apr; 118(4):258-65. PubMed ID: 19856251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiotensin II receptor blockade and insulin sensitivity in overweight and obese adults with elevated blood pressure.
    Marinik EL; Frisard MI; Hulver MW; Davy BM; Rivero JM; Savla JS; Davy KP
    Ther Adv Cardiovasc Dis; 2013 Feb; 7(1):11-20. PubMed ID: 23328189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Irbesartan prevents metabolic syndrome in rats via activation of peroxisome proliferator-activated receptor γ.
    Takai S; Jin D; Miyazaki M
    J Pharmacol Sci; 2011; 116(3):309-15. PubMed ID: 21691037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pleiotropic effects of ARB in diabetes mellitus.
    Saitoh S; Takeishi Y
    Curr Vasc Pharmacol; 2011 Mar; 9(2):136-44. PubMed ID: 21143171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.